Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study

NCT06550518 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT06550518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06550518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Completed
Start date
May 4, 2021
Completion date
December 12, 2021
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced small cell lung carcinoma